IssuerAnnouncementDetailsV2Portlet

Actions

Dr. Soliman Abdel Kader Fakeeh Hospital Co. announces its Interim Financial results for the Period Ending on 2024-03-31 ( Three Months )

4017
FAKEEH CARE
0.82 %
1445/12/27     03/07/2024 08:32:22

Element ListCurrent QuarterSimilar quarter for previous year%ChangePrevious Quarter% Change
Sales/Revenue 680.33529.4128.507662.322.719
Gross Profit (Loss) 188.58144.430.595163.3615.438
Operational Profit (Loss) 10784.1927.09395.9111.562
Net profit (Loss) 60.760.520.29763.11-3.818
Total Comprehensive Income 60.760.520.29755.98.586
All figures are in (Millions) Saudi Arabia, Riyals


Element ListCurrent PeriodSimilar period for previous year%Change
Total Shareholders Equity (after Deducting Minority Equity) 1,092.981,969.68-44.509
Profit (Loss) per Share 0.360.36
All figures are in (Millions) Saudi Arabia, Riyals


Element ListAmountPercentage of the capital (%)
Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value --
All figures are in (Millions) Saudi Arabia, Riyals


Element ListExplanation
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is Revenue in the current quarter increased by 28.5% to reach 680.3M from 529.4M in Q1 2023, driven by growing patient numbers in Jeddah and Riyadh, further supported by the Group's operate and manage (O&M) contract in NEOM.
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is Net profit in the current quarter increased by 0.3% to reach 60.7M from 60.5M in Q1 2023, with revenue growth being offset partly by higher finance charges, higher depreciation on additional investments and higher provisions for zakat. Net Profit in Q1 2023 also included a one-off finance income of 11.9M from a long-term receivable balance which was settled in September 2023.

EBITDA in the current quarter increased by 10.7% to reach 144.5M from 130.6M in Q1 2023, reflecting strong revenue growth and optimized cost structure. EBITDA in Q1 2023 also included a one-off finance income of 11.9M from a long-term receivable balance which was settled in September 2023.

The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is Revenue reached 680.3M, higher by 2.7% from 662.3M of the preceding quarter due to stronger hospital census and increased activity within the O&M contract, despite the impact of seasonality.
The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is Net profit reached 60.7M, lower 3.8% from 63.1M in the preceding quarter as a result of increased finance charges and zakat provisions.

EBITDA reached 144.5M, higher by 6.4% from 135.7M of the preceding quarter as a result of top-line growth reflecting in better operating profit.

Statement of the type of external auditor's report Unmodified conclusion
Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) NA
Reclassification of Comparison Items Yes
Additional Information NA
Attached Documents  

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.

Company Performance

FAKEEH CARE
Add To Watchlist
In your Watchlist
Add To Watchlist
Key Parameters
Last Price 39.34
Net Change 0.32 (+0.82%)
Value Traded (Sar) 5,976,509.46
Volume Traded 152,823
See The Company Profile

LoginPortletPopupv2

Actions

AddtoWatchlistv2

Actions
NO PORTLET SESSION YET